Loading…
← CockpitCompetitor Analysis › OBX Obsidian Therapeutics, Inc.Open in the cockpit ↗

Obsidian Therapeutics, Inc.OBXCompetitor analysis, valuation and peers

United States · USD·Other›Pharmaceuticals: Major
Mkt cap
$856M
US dollars, full cap
Free float
88%
of shares outstanding
$/day
$6.12M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-92.9 pp
WACC 19.8%
Hurdle
n/a
no reverse DCF
Next earnings
11 days
17 Nov 2026
Close · USD$13.87
1D+44.4%
1W-6.2%
1M+13.3%
3M-49.6%
6Mn/a
YTDn/a
1Yn/a
ATR %14.2%
52w lowhigh72.2% off high

What Obsidian Therapeutics does

Employees: 3

Obsidian Therapeutics at a glance

Size Obsidian Therapeutics (OBX) is a United States Other company (Pharmaceuticals: Major) with a market value of $856M, the 2349th largest of 3,117 United States companies the cockpit tracks. Shares closed at $13.87 on 6 Nov 2026.

Capital Return on invested capital runs 92.9 points below its cost of capital (19.8% WACC).

Next results Next results expected around 17 Nov 2026 (exchange calendar; dates can move).

Obsidian Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$635,000$0-$20,000-$259,000-$114,000
EBITDA-$30.1M-$6.04M-$14.1M-$46.7M-$51.1M
Net income$124M$149M-$19.0M-$59.1M-$62.2M
Free cash flow-$49.6M-$6.05M-$12.1M-$44.9M-$43.5M
Capital expenditure$0$0$0$59,000$25,000
Total debt$2.91M$0$151M$152M$140M

Quarterly statements and history in the cockpit →

Obsidian Therapeutics competitors and peer comparison

How Obsidian Therapeutics compares with its peers

Peer set: Same business model, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Obsidian Therapeutics against its 20 peers (data as of 6 Nov 2026)
MeasureOBXPeer medianRank in peer set
1-month return+13.3%-13.9%2nd highest of 21
Distance from 52-week high-72.2%-50.0%2nd lowest of 21
ROIC minus cost of capital-92.9 pp-4.2 pplowest of 21

Peer table

Peer set: Same business model, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Obsidian Therapeutics OBXUnited States$856Mn/an/an/an/an/an/a
Funshine Culture 300860.SZChina$858M+21%-49%-35%14.0×27.8%-24.6%
Shenzhen Lihexing 301013.SZChina$855M-3%+8%-22%10.9×n/an/a
Hangzhou Youngsun Intelligent Equipment 603901.SSChina$858M-17%+11%6%1.5×11.9%+14.7%
Longwell 6290.TWOTaiwan$854M-43%+13%15%2.6×13.7%+9.0%
Samhyun 437730.KSSouth Korea$860M-31%-18%-17%13.7×n/an/a
York Space Systems YSSUnited States$860M-82%+52%-15%1.3×n/an/a
KEDE Numerical Control 688305.SSChina$853M-29%-31%11%12.4×n/an/a
Xinjiang Beixin Road & Bridge 002307.SZChina$861M-19%-22%8%4.5×n/an/a
Blue Sail Medical 002382.SZChina$861M-24%+23%7%1.3×-6.5%-6.1%
Tellhow Sci-Tech 600590.SSChina$852M-56%-11%5%2.7×n/an/a
Beijing New Space Technology 605178.SSChina$861M-18%0%-51%16.8×n/an/a
Tianjin Benefo Tejing Electric 600468.SSChina$852M-28%+16%0%2.4×38.3%+0.2%
NOMURA 9716.TJapan$861M+4%-10%7%0.6×-8.4%+8.6%
Next Geosolutions Europe NXT.MIItaly$861M+22%+68%17%2.4×n/an/a
DOOSAN TESNA 131970.KSSouth Korea$861M-53%+3%11%3.9×17.8%+18.1%
Chongqing Millison Technologies 301307.SZChina$851M-18%+13%-11%2.1×n/an/a
Gujarat Pipavav Port GPPL.NSIndia$851M+4%+25%52%6.5×16.2%+9.6%
Towa 6315.TJapan$851M-39%+29%16%2.0×18.8%+12.8%
China Nerin Engineering 603257.SSChina$851M-21%-21%10%2.0×15.4%+5.6%
Nanjing LES Information Technology 688631.SSChina$863M-38%-31%-5%5.1×36.9%-1.1%

Questions

Which companies are Obsidian Therapeutics's closest peers?
The cockpit's peer set: Funshine Culture (300860.SZ), Shenzhen Lihexing (301013.SZ), Hangzhou Youngsun Intelligent Equipment (603901.SS), Longwell (6290.TWO), Samhyun (437730.KS), York Space Systems (YSS), KEDE Numerical Control (688305.SS), Xinjiang Beixin Road & Bridge (002307.SZ).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.